Dr Alison Jones - Dept of Medical Oncology, Royal Free Hospital, London
Dr Jones discusses the use of Trastuzumab (Herceptin) and Lapatinib as drugs to target the HER2 receptor and the possibility of combining these as part of a dual targeting approach, the drawbacks including side effects or resistance among patients and the services offered by HCA.